Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
CD20×CD3 Bispecific T-Cell Engager

Mosunetuzumab

Brand names: Lunsumio

Mosunetuzumab is a bispecific monoclonal antibody used to treat relapsed or refractory follicular lymphoma after prior lines of therapy.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a CD20 x CD3 bispecific antibody that simultaneously engages CD20 on B lymphoma cells and CD3 on T cells, redirecting T-cell-mediated killing of the malignant B cells.

Prescribing in practice

  • Cytokine release syndrome is an important risk, so step-up dosing is used at initiation and patients must be monitored and managed according to the SPC.
  • Serious infections and neurological adverse effects can occur and require prompt recognition.
  • It should be administered in a setting equipped to manage cytokine release syndrome by an experienced specialist team.

Monitoring

Monitor closely for cytokine release syndrome, neurological symptoms, infection and tumour lysis, particularly during early cycles.

Counselling the patient

  • Higher first doses are given gradually to lower the risk of a reaction.
  • Report fever, confusion, breathlessness or feeling very unwell straight away.

Evidence & guidelines

Activity in relapsed or refractory follicular lymphoma is supported by its pivotal phase 1/2 trial and reflected in MHRA approval.

Reference: CELESTIMO trial (Budde et al. Lancet 2022); NICE TA900; MHRA SPC Lunsumio; GO29781 trial (Budde et al. JCO 2022); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways